Millions of Documents.
Fifty That Matter.
Interconnected intelligence across patents, scientific literature, clinical trials, drugs, market signals, and news—grounded by Orbis AI on our patented algorithm. Not an AI wrapper.
Live Orbis demo · Bring us your toughest question
Purpose-built intelligence platforms for high-impact technology domains.
Built for |
of R&D money is wasted.
Due to insufficient use of patent & scientific information
The world's top 2,500 companies spend around US$1.45 trillion on R&D. The European Patent Office (EPO) reports that 30% of it is wasted through insufficient use of patent information.
Millions of documents.
Fifty that matter.
Orbis AI processes the entire curated evidence base across each pharma segment. Our patented algorithm synthesizes millions of data points into verified, cited answers so your team never wastes research capital.
The Scale Behind Every Orbis Answer
The Whole Evidence Base. One Patented Engine.
Orbis is built upon entire databases of documents carefully curated on each pharma segment. We use our patented algorithm to save documents, connect records, and process cited answers.
GLP-1 Ecosystem Intelligence Platform
Comprehensive pipeline, patent landscapes, and competitive dynamics across incretin mimetics, multi-agonists, and oral small molecules.
The most comprehensive intelligence platform for the incretin (GLP-1) space.
ADC (Antibody-Drug Conjugates) Intelligence
Next-generation oncology platform tracking targets, linkers, payloads, and clinical combination regimens.
Connected multi-source intelligence engineered for the antibody-drug conjugates space.
PD-1/PD-L1 Inhibitors Intelligence
Immune checkpoint inhibitor intelligence covering biosimilars, next-gen combos, and patent cliffs.
Deep-dive ecosystem intelligence for immune checkpoint inhibitors & combination regimens.
Cell & Gene Therapy
Scouting viral & non-viral vectors, CRISPR/gene editing IP landscapes, and clinical pipelines.
Deep-dive ecosystem intelligence covering delivery mechanisms, capsid engineering, IND-to-Phase 3 pipelines, and licensing.
Need Another Technology?
We’ll build a landscape for your field.The only intelligence platform you will ever need for your pharma segment. Tell us the therapeutic class, target mechanism, or biotechnology domain you need intelligence on. We curate the entire evidence base and deploy Orbis AI for your team.
The Whole Evidence Base. One Patented Engine.
Six reasons leading pharma R&D, IP, and strategy teams trust Orbis AI over generic tools and static reports.
Connected Evidence
Patents, literature, trials, market and news in one view.
Not an AI Wrapper
Built upon our own patented algorithm. No hallucinations.
Grounded Data
Every answer is cited and referenced to original records.
Continuously Updated
A living landscape, not a static report. Constantly refreshed.
Reports in Minutes
Export cited insights to PowerPoint, Excel or Word.
Built for Teams
Annotate, collect and share verified intelligence.
From Fragmented Research to
Connected Intelligence
NeurOrbis unifies the world's most critical intelligence sources and transforms disconnected data into insights that drive better decisions, faster.
Fragmented. Manual. Time-consuming.
Connected. AI-Powered. Always Current.
Do Not Take Us On Face Value.
Ask Orbis AI.
Your toughest question. Answers in seconds. Grounded in referenced evidence across patents, scientific literature, clinical trials, drugs, and market signals—on our own patented algorithm. Not an AI wrapper.
Ask a question about any technology...
Try these questions
Data Sources
“How can we engineer oral GLP-1 formulations?”
Oral bioavailability for peptide GLP-1 receptor agonists requires specialized absorption enhancers and enzymatic protection. Novo Nordisk pioneered sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) co-formulation for oral semaglutide, while newer entrants are filing patents on novel permeation carriers and enteric enteric matrices.
Concurrently, small-molecule non-peptide oral agonists (e.g., Lilly's orforglipron, Structure Therapeutics) bypass peptide degradation entirely, shifting the patent battleground toward synthesis routes and bioavailability profiles.
Evidence Mix
No hallucinations. Traceable to indexed patent and literature numbers.
Bring us your toughest question.
Book a free 30-minute demo for your team at neurorbis.com. We will run your live questions against the entire interconnected evidence base.
Built for Every Seat at the Table
From R&D and IP to BD, competitive intelligence, strategy, and investors—Orbis delivers connected, cited intelligence tailored to your seat.
Spot Emerging Technologies and White Space Early.
Identify emerging technologies, validate scientific hypotheses, uncover white-space opportunities, and prioritize high-impact innovations using connected intelligence across patents, literature, trials, market and competitive data.
Key Questions We Answer
- What technologies and mechanisms are growing fastest?
- Which problems remain unsolved?
- Which solutions are gaining traction?
- What does the competitive landscape look like?
- Which companies and research groups are leading innovation?
Outcomes You Achieve
- Prioritize high-potential R&D programs
- Accelerate early-stage discovery
- Reduce duplication of research
- Stay ahead of scientific trends
- Build stronger innovation pipelines
Connected Intelligence Sources
Smarter Decisions
- Discover breakthrough opportunities
- Monitor emerging technologies
- Identify white-space
- Validate scientific direction
- Reduce research risk
Bring us your toughest question.
Answers in seconds.
Book a free 30-minute demo for your team at neurorbis.com. We will run your live questions against 50,000+ patents, literature, clinical trials, and market signals.
Grounded in referenced evidence on our own patented algorithm. Not an AI wrapper. Export cited insights to PowerPoint, Excel, or Word.